Therapeutics - Other
1 Results were found on Technologies
Sub Category Name
Leading Researchers:
2023-0128
OGP: A CB2 Agonist Enhancing CAR-T Therapy
CAR-T therapies show promising clinical responses, yet many patients relapse due to the immunosuppressive tumor microenvironment (TME). Multiple Myeloma remains largely incurable. OUR SOLUTION Osteogenic growth peptide (OGP), a selective CB2 agonist, enhances anti-tumor immunity by reducing immunosuppressive myeloid cells and boosting cytotoxic T-cell activity. In preclinical studies, OGP demonstrated synergistic activity with CAR-T therapy, […] Read More >
